Top

Current Fungal Infection Reports

Published in:

01-12-2018 | Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Pityriasis Versicolor: Treatment Update

Authors: Martin Arce, Daniela Gutiérrez-Mendoza

Published in: Current Fungal Infection Reports | Issue 4/2018

Abstract

Purpose of Review

To address the latest treatments used for pityriasis versicolor and identify those that have proven to be effective in recent publications.

Recent Findings

Even though Malassezia spp. have shown resistance to antifungals, classical treatments continue to be effective, and other novelty therapies including light therapies have shown promising results in the treatment of this condition.

Summary

Pityriasis versicolor is a common superficial fungal infection of the skin. There are numerous and diverse topical and systemic therapeutic options that are successful for the treatment and prophylaxis of this mycosis. New substances that act against the fungus through other mechanisms of action different from those used until now are expected in the near future.

Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol. 2013;31:455–63.CrossRefPubMed

Harada K, Saito M, Sugita T, Tsuboi R. Malassezia species and their associated skin diseases. J Dermatol. 2015;42:250–7. https://doi.org/10.1111/1346-8138.12700.CrossRefPubMed

Rios-Yuil JM. Pityriasis versicolor: clinical spectrum and diagnosis. Curr Fungal Infect Rep. 2016;10:121–5. https://doi.org/10.1007/s12281-016-0261-6.CrossRef

Borelli D, Jacobs PH, NaIl L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol. 1991;25:300–5.CrossRefPubMed

Thoma W, Krämer HJ, Mayser P. Pityriasis versicolor alba. J Eur Acad Dermatol Venereol. 2005;19(2):147–52. https://doi.org/10.1111/j.1468-3083.2004.01085.x.CrossRefPubMed

Cullingham K, Hull PR. Atrophying pityriasis versicolor. CMAJ. 2014;186(10):776. https://doi.org/10.1503/cmaj.131846.CrossRefPubMedPubMedCentral

Romero-Sandoval K, Costa AA, Teixeira Sousa MG, et al. Recurrent and disseminated pityriasis versicolor: a novel clinical form consequent to Malassezia-host interaction? Med Hypotheses. 2017;109:139–44. https://doi.org/10.1016/j.mehy.2017.10.013.CrossRefPubMed

Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000;1:75–80. https://doi.org/10.2165/00128071-200,001,020-00001.CrossRefPubMed

Isa-Isa R, Cruz AC, Arenas R, Duarte Y, Linares L, Bogaert H. Pitiriasis versicolor en niños. Estudio epidemiológico y micológico de 797 casos estudiados en la República Dominicana. Med Cutan Iber Lat Am. 2002;30(1):5–8.

10.

Motta de Morais P, Souza Cunha MG, Moreira Frota MZ. Clinical aspects of patients with pityriasis versicolor seen at a referral center for tropical dermatology in Manaus, Amazonas, Brazil. An Bras Dermatol. 2010;85(6):797–803.CrossRef

11.

• Gupta A, Foley K. Antifungal treatment for pityriasis versicolor. J Fungi. 2015;1:13–29. https://doi.org/10.3390/jof1010013 A review and evaluation of studies conducted with azole antifungics and terbinafine in pityriasis versicolor is presented.CrossRef

12.

Helou J, Obeid G, Moutran R, Maatouk I. Pityriasis versicolor: a case of resistance to treatment. Int J Dermatol. 2014;53(2):e114–6. https://doi.org/10.1111/j.13654632.2012.05689.x.

13.

Findley K, Oh J, Yang J, et al. Topographic diversity of fungal and bacterial communities in human skin. Nature. 2013;000:1–4. https://doi.org/10.1038/nature12171.CrossRef

14.

Jo J-H, Kennedy EA, Kong HH. Topographical and physiological differences of the skin mycobiome in health and disease. Virulence. 2017;8:324–33. https://doi.org/10.1080/21505594.2016.1249093.CrossRefPubMed

15.

Sparber F, LeibundGut-Landmann S. Host responses to Malassezia spp in the mammalian skin. Front Immunol. 2017;8:1614. https://doi.org/10.3389/fimmu.2017.01614.CrossRefPubMedPubMedCentral

16.

Wang QM, Theelen BT, Groenewald M, Bai FY, Boekhout T. Moniliellomycetes and Malasseziomycetes, two new classes in Ustilaginomycotina. Persoonia. 2014;33:41–7. https://doi.org/10.3767/003158514X682313.CrossRefPubMedPubMedCentral

17.

Wu G, Zhao H, Li C, et al. Genus-wide comparative genomics of Malassezia delineates its phylogeny, physiology, and niche adaptation on human skin. PLoS Genet. 2015;11(11):e1005614. https://doi.org/10.1371/journal.pgen.1005614.

18.

•• Honnavar P, Prasad GS, Ghosh A, et al. Malassezia arunalokei sp. nov., a novel yeast species isolated from seborrhoeic dermatitis patients and healthy individuals from India. J Clin Microbiol. 2016. https://doi.org/10.1128/JCM.00683-16 This article introduces a new species of Malassezia found in human skin.

19.

•• Cabañes FJ, Coutinho DA, Puig L, Bragulat R, Castella G. New lipid-dependent Malassezia species from parrots. Nuevas especies lipodependientes del género Malassezia procedentes de loros. Rev Iberoam Micol. 2016;33:92–9. https://doi.org/10.1016/j.riam.2016.03.003 This publication presents another novo species of Malassezia isolated in birds.CrossRefPubMed

20.

Crespo Erchiga V, Ojeda Martos A, Vera Casaño A, Crespo Erchiga A, Sanchez FF. Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol. 2000;143(4):799–803.CrossRefPubMed

21.

Morishita N, Sei Y, Sugita T. Molecular analysis of Malassezia microflora from patients with pityriasis versicolor. Mycopathologia. 2006;161:61–5. https://doi.org/10.1007/s11046-005-0149-4.CrossRefPubMed

22.

Prohic A, Jovovic Sadikovic T, Krupalija-Fazlic M, Kuskunovic-Vlahovljak S. Malassezia species in healthy skin and in dermatological conditions. Int J Dermatol. 2016;55:494–504.CrossRefPubMed

23.

White TC, Findley K, Dawson TL Jr, et al. Fungi on the skin: dermatophytes and Malassezia. Cold Spring Harb Perspect Med. 2014;4:a019802.CrossRefPubMedPubMedCentral

24.

Cruz R, Vieille P, Giusiano G, Sosa MA. Pitiriasis versicolor por Malassezia pachydermatis: Caso clínico. Pityriasis versicolor caused by Malassezia pachydermatis: Clinical case. Bol Micol. 2010;25:37–4. https://doi.org/10.22370/bolmicol.2010.25.0.72.CrossRef

25.

Velegraki A, Cafarchia C, Gaitanis G, Iatta R, Boekhout T. Malassezia infections in humans and animals: pathophysiology, detection, and treatment. PLoS Pathog. 2015;11(1):e1004523. https://doi.org/10.1371/journal.ppat.1004523.CrossRefPubMedPubMedCentral

26.

Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996;34:287–9.CrossRefPubMed

27.

Shi TW, Zhang JA, Tang YB, et al. A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor. J Dermatol Treat. 2014:1–4. https://doi.org/10.3109/09546634.2014.921661.

28.

Dias MFRG, Quaresma-Santos MVP, Bernardes-Filho F, et al. Update on therapy for superficial mycoses: review article part I. An Bras Dermatol. 2013;88(5):764–74. https://doi.org/10.1590/abd1806-4841.20131996.CrossRefPubMedPubMedCentral

29.

Sharquie KE, Al-Hamamy HM, Noaimi AA, Al-Shawi IA. Treatment of pityriasis versicolor using 1% diclofenac gel and clotrimazole cream (comparative therapeutic study). JSSDDS. 2011;15:19–23. https://doi.org/10.1016/j.jssdds.2010.10.004.CrossRef

30.

Fernández-Vozmediano JM, Armario-Hita JC. Etiopatogenia y tratamiento de la pitiriasis versicolor. Med Clin (Barc). 2006;126:7–13.CrossRef

31.

Bamford JTM, Flores-Genuino RNS, Ray S, et al. Interventions for the treatment of pityriasis versicolor. Cochrane Database Syst Rev 2014; Issue 7. Art. No.: CD011208. https://doi.org/10.1002/14651858.CD011208.

32.

Reeder NL, Kaplan J, Xu J, et al. Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins. Antimicrob Agents Chemother. 2011;55:5753–60. https://doi.org/10.1128/AAC.00724-11.CrossRefPubMedPubMedCentral

33.

Saunders CW, Scheynius A, Heitman J. Malassezia fungi are specialized to live on skin and associated with dandruff, eczema, and other skin diseases. PLoS Pathog. 2012;8(6):e1002701. https://doi.org/10.1371/journal.ppat.1002701.CrossRefPubMedPubMedCentral

34.

• Hald M, Arendrup MC, Svejgaard EL, et al. Evidence-based Danish guidelines for the treatment of Malassezia – related skin diseases. Acta Derm Venereol. 2015;95:12–9 Analysis and treatment recommendations for Malassezia infections based on evidence level.CrossRefPubMed

35.

Pérez AR. Resultados del tratamiento con yodo salicílico y ketoconazol en la pitiriasis versicolor. Rev. haban cienc méd [Internet]. 2008;7:1–10 http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2008000100019&lng=es.

36.

Rivard SC. Pityriasis versicolor: avoiding pitfalls in disease diagnosis and therapy. Mil Med. 2013;178(8):904–6. https://doi.org/10.7205/MILMED-D-13-00057.CrossRefPubMed

37.

Heeres J, Meerpoel L, Lewi P. Conazoles. Molecules. 2010;15:4129–88. https://doi.org/10.3390/molecules15064129.CrossRefPubMedPubMedCentral

38.

• Angiolella L, Carradori S, Maccallini C, Giusiano G, Supuran CT. Targeting Malassezia species for novel synthetic and natural antidandruff agents. Curr Med Chem. 2017;24:1–21. https://doi.org/10.2174/0929867324666170404110631 Article review of new treatments focused on Malassezia infections.CrossRef

39.

Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2012;2012(713687):26. https://doi.org/10.1155/2012/713687.CrossRef

40.

Scorzoni L, de Paula e Silva ACA, Marcos CM, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol. 2017;8:36. https://doi.org/10.3389/fmicb.2017.00036.CrossRefPubMedPubMedCentral

41.

Fuentefria AM, Pippi B, Dalla Lana DF, Donato KK, de Andrade SF. Antifungals discovery: an insight into new strategies to combat antifungal resistance. Lett Appl Microbiol. 2018;66(1):2–13. https://doi.org/10.1111/lam.12820.CrossRefPubMed

42.

•• Iatta R, Puttilli MR, Immediato D, et al. The role of drug efflux pumps in Malassezia pachydermatis and Malassezia furfur defense against azoles. Mycoses 2016; 1–5. https://doi.org/10.1111/myc.12577. This publication explains one of the resistance mechanisms Malassezia spp. anti-fungal against.

43.

Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol. 2000;142:758–65.CrossRefPubMed

44.

Cafarchia C, Iatta R, Immediato D, Puttilli R, Otranto D. Azole susceptibility of Malassezia pachydermatis and Malassezia furfur and tentative epidemiological cut-off values. Med Mycol. 2015;00:1–6. https://doi.org/10.1093/mmy/myv049.CrossRef

45.

Miranda KC, de Araujo CR, Costa CR, et al. Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents. 2007;29(3):281–94. https://doi.org/10.1016/j.ijantimicag.2006.09.016.CrossRefPubMed

46.

Rojas FD, Córdoba SB, Sosa MA, et al. Antifungal susceptibility testing of Malassezia yeast: comparison of two different methodologies. Mycoses. 2016:1–8. https://doi.org/10.1111/myc.12556.

47.

Leong C, Buttafuoco A, Glatz M, Bosshard PP. Antifungal susceptibility testing of Malassezia spp. with an optimized colorimetric broth microdilution method. J Clin Microbiol. 2017;55:1883–93. https://doi.org/10.1128/JCM.00338-17.CrossRefPubMedPubMedCentral

48.

Sepahvand A, Eliasy H, Rahimi H, et al. Phytotherapy for tinea versicolor. Int J Health Med Curr Res. 2017;2:592–9. https://doi.org/10.22301/IJHMCR.2528-3189.592.CrossRef

49.

Rhimi W, Salem IB, et al. Chemical composition, antibacterial and antifungal activities of crude Dittrichia viscosa (L.) greuter leaf extracts. Molecules. 2017;22(942):1–13. https://doi.org/10.3390/molecules22070942.CrossRef

50.

• Ianiri G, Applen Clancey S, Lee SC, Heitman J. FKBP12-dependent inhibition of calcineurin mediates immunosuppressive antifungal drug action in Malassezia. mBio. 8:e01752–17. https://doi.org/10.1128/mBio.01752-17 This study paves the use of calcineurin inhibitors as alternatives in the treatment of pityriasis versicolor.

51.

Sepaskhah M, Sadat MS, Pakshir K, Bagheri Z. Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: a single blind, randomized clinical trial. Mycoses. 2017;60(5):338–42. https://doi.org/10.1111/myc.12598.CrossRefPubMed

52.

Qiao J, Li R, Ding Y, Fang H. Photodynamic therapy in the treatment of superficial mycoses: an evidence-based evaluation. Mycopathologia. 2010;170(5):339–43. https://doi.org/10.1007/s11046-010-9325-2.CrossRefPubMed

53.

Dai T, Fuchs BB, Coleman JJ, et al. Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front Microbiol. 2012;3:1–16. https://doi.org/10.3389/fmicb.2012.00120.CrossRef

54.

Penjweini R, Mokmeli S, Becker K, Dodt HU, Saghafi S. Effects of UV-, visible-, near-infrared beams in three therapy resistance case studies of fungal skin infections. OPJ. 2013;3:1–10. https://doi.org/10.4236/opj.2013.37A001.CrossRef

55.

Kim YJ, Kim YC. Successful treatment of pityriasis versicolor with 5-aminolevulinic acid photodynamic therapy. Arch Dermatol. 2007;143:1218–9. https://doi.org/10.1001/archderm.143.9.1218.CrossRefPubMed

56.

Abreu L, Adriano AR, Félix Bravo B, et al. Treatment of pityriasis versicolor with photodynamic therapy. J Am Acad Dermatol 2013; 68(4):S1, AB131. https://doi.org/10.1016/j.jaad.2012.12.542

57.

Gilaberte Y, Aspiroz C, Alejandre C, Rezusta A. Crecimiento de Malassezia en piel peritumoral tras terapia fotodinámica con metil-5-aminolevulinato para queratosis actínica y cáncer de piel no melanoma. Actas Dermosifiliogr. 2015;106:70–1.CrossRefPubMed

58.

Balevi A, Üstüner P, Kakşi SA, Özdemir M. Narrow-band UV-B phototherapy: an effective and reliable treatment alternative for extensive and recurrent pityriasis versicolor. J Dermatol Treat. 2017;9:1. https://doi.org/10.1080/09546634.2017.1364690.CrossRef

59.

Ibekwea PU, Ogunbiyib AO, Ruzickac T, Sa‘rdyc M. Quality of life determinants in secondary school students with pityriasis versicolor. J Egypt Women Dermatol Soc. 2015;12:49–54. https://doi.org/10.1097/01.EWX.0000452297.12250.87.CrossRef

Title: Pityriasis Versicolor: Treatment Update
Authors: Martin Arce
Daniela Gutiérrez-Mendoza
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Fungal Infection Reports / Issue 4/2018
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-018-0328-7

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Patients with Primary Immunodeficiencies: How Are They at Risk for Fungal Disease?

Association of Malassezia to Atopic Dermatitis

Emergence of Resistance to Fluconazole in Candida albicans Isolated From Vaginal Discharge

Diagnosing Invasive Mold Infections: What Is Next

Correction to: Pressing Priorities for Mycetoma Control and Prevention

Onychomycosis in Children with Down Syndrome

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage